ESPR Company Profile and Key Details

Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed at $2.08 USD, losing -$0.09 (-4.33%) from the previous close of $2.17. The stock is currently mid-range between its 52-week high and low $0.69 and $4.18. With a market capitalization of about $431.62 million, Esperion Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 5.32 million shares, volume is running light vs its 52-week average. Headquartered in Ann Arbor, MI, Esperion Therapeutics, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Sheldon L. Koenig, the company employs approximately 304 people and listed since June 26, 2013. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.

Short-term trend indicators are mixed aligned (SMA20 -1.75%, SMA50 -4.53%, SMA200 36.03%). The stock’s 14-day RSI is 47.3 (neutral), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.52% below its high and over 385.2% above its low. Average 10-day trading volume of 7.95 million shares is significantly above the 3-month average of 5.06 million, indicating heightened recent market interest.

Esperion Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Esperion Therapeutics, Inc. generated EPS of -$0.54 over the past year. Five-year average earnings growth is 40.11%. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at $0.27. Next year's EPS is expected at $98.27. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $5.00. The high target offers 680.49% upside. The low target suggests 143.9% downside. The mean target is $10.20. This offers 397.56% upside. Esperion Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -297.65%. The prior quarter beat by -88.24%. Over the last six quarters, Apple has recorded several small beats. These include 118.67% in August 12, 2024.

Esperion Therapeutics, Inc. has 201.62 million shares outstanding. The public float is 199.76 million shares, elevated short interest at 11.60% of float. This equals 23.13 million shares. The short ratio is 4.77 days. Institutional investors hold 50.9% of the float. Insiders own 0.56%. BIOTECH TARGET N V holds 4.48 million shares, Koenig Sheldon L. has 2.17 million shares and JANNEY DANIEL has 1.48 million shares. Over the past six months, insider transactions show net selling. They sold 101.50 thousand shares across 7 transactions.